The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Revision of old position papers – September 2019
Position paper drafts/revision for GA 2020 | DECISION NEEDED
- Board needs to decide which position papers should be worked on for the GA 2020
- Detailed information on the need to revise EAHP’s ‘old’ positions/adopt a position on compounding is included HERE
January 2011 | Statement on Hospital Pharmacy Specialisation | Misses reference to Statements + CTF | high priority |
January 2011 | Statement on Patient Safety | Misses reference to Statements | low priority |
June 2012 | Statement on the need for barcoding of the single dose administered in hospitals | Refers to outdated FMD information | low to medium priority |
June 2012 | Statement on clinical trials | Difficult to update since it comments on the revision of the clinical trial legislation –> new document needed | medium priority |
July 2013 | Statement on public spending austerity and its impact upon access to medicines and patient safety | No revision needed | – |
August 2013 | Statement on medical device regulation | Difficult to update since it comments on the revision of the medical device legislation –> new document needed | low to medium priority |
June 2014 | Statement on sustainable and equitable access to medicines | Position on pricing and reimbursement requested by GA in 2018 | high priority |
June 2016 | Position Paper on SmPC and density information | Possible extension in the future requested by GA in 2016 | low priority |
new | Position on compounding | Core activity of HPs without a position by EAHP | medium priority |
Position paper draft medical devices | DECISION NEEDED
- Feedback needs to be provided to EuroPharmat regarding their proposal (see HERE)